AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.